FDA OKs Abbott's next-gen defibrillators

• Abbott (NYSE:ABT) announces the FDA nod for its Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices.
• The company says new features include a patient-preferred design without compromising battery life and MRI compatibility and a smartphone app for improved remote monitoring.
• The Gallant system was CE Mark'd in February.
• Shares up 1% premarket on light volume.

Comments

[AlieGee]

"It is estimated that as many as 6.1 million people in the United States battle cardiac arrhythmias, or abnormal heart rhythms,1 and ICDs are used to help reduce the risks of life-threatening arrhythmias."

I wouldn't doubt seeing higher numbers now that so many are working from home and not
getting even walking exercise -